دورية أكاديمية
أعرض في EDS

Public neoantigens in breast cancer immunotherapy (Review).

التفاصيل البيبلوغرافية
العنوان: Public neoantigens in breast cancer immunotherapy (Review).
المؤلفون: Sueangoen N; Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand., Thuwajit P; Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand., Yenchitsomanus PT; Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE‑CIT), Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand., Thuwajit C; Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
المصدر: International journal of molecular medicine [Int J Mol Med] 2024 Jul; Vol. 54 (1). Date of Electronic Publication: 2024 Jun 21.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9810955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-244X (Electronic) Linking ISSN: 11073756 NLM ISO Abbreviation: Int J Mol Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Athens, Greece : D.A. Spandidos, [1998-
مواضيع طبية MeSH: Breast Neoplasms*/therapy , Breast Neoplasms*/immunology , Breast Neoplasms*/genetics , Antigens, Neoplasm*/immunology , Antigens, Neoplasm*/genetics , Immunotherapy*/methods, Humans ; Female ; Mutation
مستخلص: Among women globally, breast cancer is the most prevalent cancer and the leading cause of cancer‑related death. Interestingly, though genetic mutations contribute to the disease, <15% of women diagnosed with breast cancer have a family history of the disease, suggesting a prevalence of sporadic genetic mutations in breast cancer development. In the rapidly rising field of cancer genomics, neoantigen‑based immunotherapy has come to the fore. The investigation of novel proteins arising from unique somatic mutations or neoantigens have opened a new pathway for both individualized and public cancer treatments. Because they are shared among individuals with similar genetic changes, public neoantigens provide an opportunity for 'off‑the‑shelf' anticancer therapies, potentially extending the benefits to a wider patient group. The present review aimed to highlight the role of shared or public neoantigens as therapeutic targets for patients with breast cancer, emphasizing common hotspot mutations of certain genes identified in breast cancer. The clinical utilization of public neoantigen‑based therapies for breast cancer treatment were also discussed.
References: Clin Genet. 2018 May;93(5):1063-1068. (PMID: 29206279)
J Clin Invest. 2019 Mar 1;129(3):1109-1114. (PMID: 30714987)
Front Bioeng Biotechnol. 2020 Jul 13;8:702. (PMID: 32754579)
Nat Rev Drug Discov. 2009 Aug;8(8):627-44. (PMID: 19644473)
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. (PMID: 26122181)
Front Immunol. 2019 Aug 07;10:1856. (PMID: 31440245)
FEBS J. 2010 Aug;277(15):3086-96. (PMID: 20608970)
Cells. 2022 Jul 25;11(15):. (PMID: 35892586)
Nature. 2013 Jul 11;499(7457):214-218. (PMID: 23770567)
J Clin Oncol. 2008 Mar 10;26(8):1247-52. (PMID: 18250350)
Lancet Glob Health. 2016 Sep;4(9):e609-16. (PMID: 27470177)
Front Oncol. 2022 Mar 21;12:786438. (PMID: 35387130)
Science. 2018 Mar 23;359(6382):1355-1360. (PMID: 29567706)
Cancer Immunol Immunother. 2002 Dec;51(11-12):669-73. (PMID: 12439613)
J Cell Biochem. 2017 Dec;118(12):4728-4734. (PMID: 28513990)
J Exp Clin Cancer Res. 2010 Aug 27;29:117. (PMID: 20799949)
Ann N Y Acad Sci. 1993 Jun 11;684:119-26. (PMID: 8317825)
DNA Repair (Amst). 2022 Jun;114:103330. (PMID: 35378404)
Osteoarthritis Cartilage. 2020 Apr;28(4):400-409. (PMID: 32081707)
Breast Cancer Res. 2014 Jun 20;16(3):R65. (PMID: 24951027)
Nat Med. 2019 May;25(5):767-775. (PMID: 31011208)
J Exp Med. 2018 Jan 2;215(1):5-7. (PMID: 29269561)
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):153-164. (PMID: 28816141)
Front Oncol. 2022 Mar 18;12:825484. (PMID: 35372075)
Nat Biotechnol. 2016 Feb;34(2):155-63. (PMID: 26619011)
Annu Rev Immunol. 1994;12:337-65. (PMID: 8011285)
Hum Mutat. 2006 Jan;27(1):14-20. (PMID: 16278824)
J Transl Med. 2004 Apr 16;2(1):12. (PMID: 15090064)
Science. 1995 Sep 1;269(5228):1281-4. (PMID: 7652577)
PLoS One. 2013 May 21;8(5):e64268. (PMID: 23704984)
Nat Rev Immunol. 2011 Nov 11;11(12):823-36. (PMID: 22076556)
Adv Anat Pathol. 2020 Jan;27(1):27-35. (PMID: 31045583)
Breast Cancer Res Treat. 2012 Jun;133(3):1097-104. (PMID: 22350789)
Nature. 2017 Jul 13;547(7662):217-221. (PMID: 28678778)
Int J Mol Sci. 2022 Sep 04;23(17):. (PMID: 36077528)
Mol Endocrinol. 1996 Nov;10(11):1388-98. (PMID: 8923465)
Histopathology. 2014 Sep;65(3):340-52. (PMID: 24612173)
PLoS One. 2013;8(3):e57581. (PMID: 23469205)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
Int J Oncol. 2022 May;60(5):. (PMID: 35383859)
Semin Cancer Biol. 2021 Jul;72:65-75. (PMID: 31698088)
Clinics (Sao Paulo). 2012 Nov;67(11):1285-90. (PMID: 23184205)
Breast Cancer (Dove Med Press). 2017 May 12;9:331-335. (PMID: 28553140)
Science. 2013 Mar 29;339(6127):1546-58. (PMID: 23539594)
J Biol Chem. 2009 Jul 3;284(27):18302-10. (PMID: 19423707)
Carcinogenesis. 2012 Nov;33(11):2007-17. (PMID: 22822097)
BMC Cancer. 2018 Mar 22;18(1):315. (PMID: 29566657)
Pharmaceutics. 2021 May 14;13(5):. (PMID: 34069059)
N Engl J Med. 2021 Feb 4;384(5):428-439. (PMID: 33471991)
Nat Med. 2019 Oct;25(10):1526-1533. (PMID: 31570822)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nature. 2012 Oct 4;490(7418):61-70. (PMID: 23000897)
Arch Pathol Lab Med. 2016 Aug;140(8):806-14. (PMID: 27472239)
Vaccines (Basel). 2022 Sep 22;10(10):. (PMID: 36298462)
Sci Rep. 2022 Jan 12;12(1):599. (PMID: 35022469)
Nature. 2016 May 02;534(7605):47-54. (PMID: 27135926)
N Engl J Med. 2014 Aug 7;371(6):497-506. (PMID: 25099575)
Cancer Immunol Res. 2019 Apr;7(4):534-543. (PMID: 30709841)
J Mol Evol. 2010 Dec;71(5-6):444-57. (PMID: 21057781)
Drugs. 2020 Apr;80(6):601-607. (PMID: 32248356)
Maedica (Bucur). 2015 Jun;10(2):185-191. (PMID: 28275416)
J Clin Oncol. 2022 Jun 1;40(16):1741-1754. (PMID: 35104158)
Mod Pathol. 2011 Feb;24(2):157-67. (PMID: 21076464)
Genome Med. 2019 Aug 28;11(1):56. (PMID: 31462330)
J Clin Oncol. 2005 Feb 1;23(4):741-50. (PMID: 15613700)
Oncoimmunology. 2020 Apr 1;9(1):1744947. (PMID: 32523802)
BMC Cancer. 2022 Sep 21;22(1):1002. (PMID: 36131248)
Breast Cancer Res Treat. 2007 Nov;105(3):267-76. (PMID: 17221156)
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. (PMID: 35714673)
Lancet. 2013 May 25;381(9880):1827-34. (PMID: 23639488)
Breast Cancer Res Treat. 2011 Apr;126(3):601-7. (PMID: 20521098)
Med Princ Pract. 2021;30(1):1-16. (PMID: 32841942)
Nat Genet. 2013 Dec;45(12):1439-45. (PMID: 24185512)
Oncogene. 2008 Sep 18;27(41):5477-85. (PMID: 18794882)
Vaccine. 2011 May 17;29(22):3832-6. (PMID: 21470580)
J Clin Oncol. 2010 Mar 1;28(7):1099-105. (PMID: 20100959)
Cancer. 2012 Sep 1;118(17):4354-62. (PMID: 22252842)
J Exp Med. 1999 Sep 6;190(5):705-15. (PMID: 10477554)
Mol Genet Genomic Med. 2019 Dec;7(12):e1001. (PMID: 31637877)
N Engl J Med. 2016 Dec 8;375(23):2255-2262. (PMID: 27959684)
Cancer Discov. 2019 Aug;9(8):1022-1035. (PMID: 31164343)
JAMA Oncol. 2023 Jan 1;9(1):71-78. (PMID: 36326756)
Ann Oncol. 2011 Aug;22(8):1736-47. (PMID: 21709140)
Mol Cancer. 2024 Mar 16;23(1):56. (PMID: 38491381)
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50. (PMID: 20952405)
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8500-5. (PMID: 26339424)
J Clin Oncol. 2013 Jan 10;31(2):203-9. (PMID: 23233704)
Clin Epidemiol. 2019 Jul 11;11:543-561. (PMID: 31372057)
BMC Cancer. 2019 Mar 4;19(1):200. (PMID: 30832597)
BMJ. 2015 Apr 22;350:h988. (PMID: 25904595)
Nature. 2003 Feb 27;421(6926):961-6. (PMID: 12607005)
Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004. (PMID: 25717386)
Sci Rep. 2020 Apr 27;10(1):7073. (PMID: 32341426)
Anticancer Res. 2010 Dec;30(12):5091-7. (PMID: 21187495)
BMC Genomics. 2016 Jun 23;17 Suppl 2:394. (PMID: 27356755)
Nature. 2009 Apr 9;458(7239):719-24. (PMID: 19360079)
Annu Rev Pathol. 2015;10:25-50. (PMID: 25340638)
Int J Mol Sci. 2022 Dec 12;23(24):. (PMID: 36555391)
J Clin Oncol. 2010 Jan 1;28(1):92-8. (PMID: 19933921)
Br J Cancer. 2005 Oct 31;93(9):1046-52. (PMID: 16175185)
Cell. 2020 Dec 10;183(6):1634-1649.e17. (PMID: 33259803)
Ann Oncol. 2014 Sep;25(9):1729-1735. (PMID: 25009010)
BMC Cancer. 2016 Aug 11;16:622. (PMID: 27515171)
Nat Med. 2022 May;28(5):946-957. (PMID: 35484264)
Invest New Drugs. 2014 Aug;32(4):670-81. (PMID: 24652201)
Cancer Res. 1997 Apr 1;57(7):1244-9. (PMID: 9102207)
EBioMedicine. 2017 Sep;23:20-24. (PMID: 28888924)
Clin Cancer Res. 2005 Aug 15;11(16):5678-85. (PMID: 16115903)
Cancer Immunol Res. 2017 Jul;5(7):516-523. (PMID: 28619968)
Breast. 2015 Nov;24 Suppl 2:S26-35. (PMID: 26253814)
Cancer. 2010 Mar 15;116(6):1431-9. (PMID: 20131351)
Cancer Discov. 2020 Oct;10(10):1475-1488. (PMID: 32699032)
Horm Cancer. 2018 Aug;9(4):215-228. (PMID: 29736566)
Cell. 2019 May 16;177(5):1330-1345.e18. (PMID: 30982598)
Nature. 2013 Aug 22;500(7463):415-21. (PMID: 23945592)
Nat Rev Cancer. 2011 Dec 23;12(1):68-78. (PMID: 22193408)
Lancet Oncol. 2016 Jun;17(6):811-821. (PMID: 27155741)
Sci Rep. 2021 Jun 30;11(1):13590. (PMID: 34193879)
Clin Cancer Res. 2020 Jan 15;26(2):450-464. (PMID: 31857430)
BMC Cancer. 2022 Nov 17;22(1):1185. (PMID: 36397030)
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):. (PMID: 27881444)
Cancer Res. 2011 Jul 1;71(13):4344-51. (PMID: 21482677)
Nat Rev Cancer. 2001 Dec;1(3):233-40. (PMID: 11902578)
Int J Clin Exp Pathol. 2020 Mar 01;13(3):332-346. (PMID: 32269671)
Cancer Immunol Res. 2022 Aug 3;10(8):932-946. (PMID: 35749374)
Thorac Cancer. 2020 Jul;11(7):1861-1868. (PMID: 32412177)
Breast Cancer Res. 2018 Oct 1;20(1):115. (PMID: 30285883)
Curr Opin Obstet Gynecol. 2010 Feb;22(1):72-8. (PMID: 19841585)
Cancer Res. 2015 Jan 1;75(1):5-10. (PMID: 25524899)
Science. 2014 Mar 28;343(6178):1466-70. (PMID: 24675953)
J Clin Oncol. 2014 Sep 20;32(27):2951-8. (PMID: 25071141)
Ann Transl Med. 2019 Apr;7(8):179. (PMID: 31168460)
Lancet. 2015 Nov 21;386(10008):2078-2088. (PMID: 26386540)
Ann Oncol. 2020 Mar;31(3):387-394. (PMID: 32067680)
Nature. 2007 Jul 26;448(7152):439-44. (PMID: 17611497)
Cancers (Basel). 2019 Feb 24;11(2):. (PMID: 30813491)
J Clin Oncol. 2006 Jul 20;24(21):3381-7. (PMID: 16801628)
BMC Clin Pathol. 2015 Nov 18;15:20. (PMID: 26587011)
Nat Rev Cancer. 2004 Sep;4(9):665-76. (PMID: 15343273)
J Immunol. 2015 Dec 1;195(11):5117-22. (PMID: 26589749)
Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. (PMID: 30089255)
J Clin Oncol. 2015 Mar 1;33(7):709-15. (PMID: 25605856)
Cancer Immunol Immunother. 2024 Feb 13;73(3):43. (PMID: 38349410)
Int J Cancer. 2002 Apr 20;98(6):864-72. (PMID: 11948464)
Ann Oncol. 2016 Aug;27(8):1532-8. (PMID: 27194814)
Cells. 2022 Nov 29;11(23):. (PMID: 36497091)
Blood. 2017 Nov 2;130(18):1985-1994. (PMID: 28860210)
Breast Cancer Res. 2020 May 13;22(1):45. (PMID: 32404150)
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. (PMID: 12826609)
فهرسة مساهمة: Keywords: breast cancer; hotspot mutation; immunotherapy; public neoantigen
المشرفين على المادة: 0 (Antigens, Neoplasm)
تواريخ الأحداث: Date Created: 20240621 Date Completed: 20240621 Latest Revision: 20240626
رمز التحديث: 20240627
مُعرف محوري في PubMed: PMC11188978
DOI: 10.3892/ijmm.2024.5388
PMID: 38904202
قاعدة البيانات: MEDLINE
الوصف
تدمد:1791-244X
DOI:10.3892/ijmm.2024.5388